CClinicalTrials.gg
CompletedNCT04998617Updated Aug 9, 2023

Effects of Curcumin-containing Toothpaste on Dental Biofilm and Associated Oral Halitosis

An interventional study of Toothpaste with curcumin and Toothpaste without curcumin in Halitosis, sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Purpose: To investigate the short-term clinical effect of curcumin-containing toothpaste on halitosis as compared to placebo and to assess potential shifts in the composition of dental biofilm associated with the use of curcumin-containing toothpaste

Participants: This clinical study will 30 adult participants under prophylactic or periodontal maintenance protocol.

Procedures (methods): Participants will be included and throughout the protocol will not allow the use any other oral hygiene products except standard manual toothbrush and study toothpaste (either test -curcumin-containing or placebo). Additionally participants will be instructed to odiferous foods such as onions, garlic and spices. At each of the three examination sessions, Plaque Index (six sites, O'Leary) and volatile sulphur compounds (VSC) will be measured.

02

Conditions studied

  • Halitosis

Browse trials for

03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participants must be adult males or females between the ages of 18 and 65 years (inclusive) reporting halitosis
  • Participants must be able and willing to follow study procedures and instructions
  • Participants must have read, understood and signed an informed consent form
  • Participants must present with at least 8 teeth in the functional dentition and with at least 4 teeth in each posterior sextant, 3 of which are adjacent teeth with interproximal papilla in each posterior sextant that will have the stent
  • Participants must be in good general health

Exclusion criteria

Exclusion Criteria

  • Patients ongoing restorative or periodontal dental treatment or any other medical treatment
  • Subjects with any pathological alterations of the oral mucosa
  • Any known allergy to previously used oral hygiene products or any known allergy to any of the ingredients of the study products, which are used during the study
  • Pregnant women
  • Subjects with untreated periodontitis or active caries lesion
  • Subjects diagnosed with acute sinusitis, bronchitis or tonsillitis
  • Subjects under treatment on medications which can cause malodor, e.g. amphetamines, nitrates and nitrites
  • Known diabetes, liver or kidney insufficiency
  • Subjects diagnosed with reduced salivary flow due to pathological reasons (e.g. Sjögren syndrome)
  • Subjects who underwent preventive periodontal treatment, i.e. oral prophylaxis treatment, within the last week
  • Volunteers unwilling to abstain from additional oral hygiene (only tooth brushing allowed) particularly mouthrinse, chewing gums, breath strips, etc and alcohol 12 h prior the first measurement at the study site and until the completion of all measurements
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Toothpaste Containing Curcumin

    After screening, participants will be randomly assigned to receive toothpaste that contains 0.5% curcumin.

    Other: Toothpaste with curcumin

  • Placebo comparator
    Toothpaste Without Curcumin

    After screening, participants will be randomly assigned to receive toothpaste that does not contain curcumin.

    Other: Toothpaste without curcumin

Interventions

  • OtherToothpaste with curcumin

    Subjects will be given toothpaste to be used during this study with 0.5% curcumin

  • OtherToothpaste without curcumin

    Subjects will be given toothpaste to be used during this study without curcumin

05

What researchers measure

Primary outcomes

  1. Volatile Sulphur Compounds (VSC) at day 7

    Volatile Sulphur Compounds (VSC) values for all subjects will be recorded. F-tests will be used to compare the curcumin group with the placebo group at each timepoint. P-values less than 0.05 will be considered statistically significant. Analyses will be performed using SAS Version 9.4 (SAS Institute, Cary NC).

    Time frame: day 7

  2. Volatile Sulphur Compounds (VSC) at day 14

    Volatile Sulphur Compounds (VSC) values for all subjects will be recorded. F-tests will be used to compare the curcumin group with the placebo group at each timepoint. P-values less than 0.05 will be considered statistically significant. Analyses will be performed using SAS Version 9.4 (SAS Institute, Cary NC).

    Time frame: day 14

  3. Volatile Sulphur Compounds (VSC) at day 21

    Volatile Sulphur Compounds (VSC) values for all subjects will be recorded. F-tests will be used to compare the curcumin group with the placebo group at each timepoint. P-values less than 0.05 will be considered statistically significant. Analyses will be performed using SAS Version 9.4 (SAS Institute, Cary NC).

    Time frame: day 21

  4. Repeated Measures Regression of Volatile Sulphur Compounds (VSC)

    A repeated measures regression with VSC as the response and treatment (curcumin or negative control) and time (7, 14 or 21 days) as predictors. An autoregressive correlation matrix will be used to account for the correlation between repeated measures within subject.

    Time frame: baseline, 21 days

06

Study locations

1 site
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
07

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.

Supporting information: Study protocol

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04998617
Lead sponsor
University of North Carolina, Chapel Hill
Collaborators
Colgate Palmolive
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
May 24, 2022
Primary completion
May 5, 2023
Completion
May 5, 2023
Last update
Aug 9, 2023

Study contacts

Antonio Moretti, DDS, MS
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion